Interleukin 34, from pathogenesis to clinical applications

Cytokine

Volumn 99, Issue , 2017, Pages 139-147

  Baghdadi, Muhammad ^a   Endo, Hiraku ^a   Tanaka, Yoshino ^a   Wada, Haruka ^a   Seino, Ken ichiro ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

Author keywords

Autoimmune diseases; Cancer; IL 34; Infection; Inflammation

Indexed keywords

INTERLEUKIN 34; INTERLEUKIN DERIVATIVE;

ACUTE HEART FAILURE; ACUTE KIDNEY FAILURE; ALZHEIMER DISEASE; ATOPIC DERMATITIS; BILE DUCT CARCINOMA; BREAST CANCER; CHRONIC HEPATITIS C; CHRONIC KIDNEY FAILURE; CORONARY ARTERY DISEASE; CROHN DISEASE; DIABETES MELLITUS; EQUINE INFECTIOUS ANEMIA; HEART FAILURE; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLUENZA A; KIDNEY TRANSPLANTATION; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; LUNG CANCER; NONALCOHOLIC FATTY LIVER; OBESITY; OSTEOSARCOMA; PATHOGENESIS; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; ULCERATIVE COLITIS; ANIMAL; BIOLOGICAL MODEL; DISEASES; METABOLISM;

ANIMALS; DISEASE; HUMANS; INTERLEUKINS; MODELS, BIOLOGICAL;

EID: 85028776089     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2017.08.020     Document Type: Review

References (75)

1. Lin, H., Lee, E., Hestir, K., Leo, C., Huang, M., Bosch, E., et al. Discovery of a cytokine and its receptor by functional screening of the extracellular proteome. Science 320 (2008), 807–811.
2. Foucher, E., Blanchard, S., Preisser, L., Garo, E., Ifrah, N., Guardiola, P., et al. IL-34 induces the differentiation of human monocytes into immunosuppressive macrophages; antagonistic effects of GM-CSF and IFNγ. PLOS ONE, 8, 2013, e56045.
3. Chen, Z., Buki, K., Vääräniemi, J., Gu, G., Väänänen, K., The critical role of IL-34 in osteoclastogenesis. PLOS ONE, 6(4), 2013, e18689.
4. Chihara, T., Suzu, S., Hassan, R., Chutiwitoonchai, N., Hiyoshi, M., Motoyoshi, K., et al. IL-34 and M-CSF share the receptor Fms but are not identical in biological activity and signal activation. Cell Death Differ. 17 (2010), 1917–1927.
5. Barve, R., Zack, M., Weiss, D., Song, R., Beidler, D., Head, R., Cytokine Transcriptional profiling and pathway analysis of CSF-1 and IL-34 effects on human monocyte differentiation. Cytokine 63 (2013), 10–17.
6. Wei, S., Nandi, S., Chitu, V., Yeung, Y., Yu, W., Huang, M., et al. Functional overlap but differential expression of CSF-1 and IL-34 in their CSF-1 receptor-mediated regulation of myeloid cells. J. Leukoc. Biol. 88 (2010), 495–505.
7. Wang, Y., Szretter, K., Vermi, W., Gilfillan, S., Rossini, C., Cella, M., et al. IL-34 is a tissue-restricted ligand of CSF1R required for the development of Langerhans cells and microglia. Nat. Immunol. 13:8 (2012), 753–760.
8. Wang, Y., Colonna, M., Interkeukin-34, a cytokine crucial for the differentiation and maintenance of tissue resident macrophages and Langerhans cells. Eur. J. Immunol. 44 (2014), 1575–1581.
9. Greter, M., Lelios, I., Pelczar, P., Hoeffel, G., Price, J., Leboeuf, M., et al. Stroma-derived interleukin-34 controls the development and maintenance of Langerhans Cells and the maintenance of microglia. Immunity 37:6 (2012), 1050–1060.
10. Yu, Y., Yang, D., Qiu, L., Okamura, H., Guo, J., Haneji, T., Tumor necrosis factor-α induces interleukin-34 expression through nuclear factor–κB activation in MC3T3-E1 osteoblastic cells. Mol. Med. Rep. 10 (2014), 1371–1376.
11. Eda, H., Shimada, H., Beidler, D., Monahan, J., Proinflammatory cytokines, IL-1β and TNF-α, induce expression of interleukin-34 mRNA via JNK- and p44/42 MAPK-NF-κB pathway but not p38 pathway in osteoblasts. Rheumatol. Int. 31 (2011), 1525–1530.
12. Chemel, M., Goff, B., Brion, R., Cozic, C., Berreur, M., Amiaud, J., et al. Interleukin 34 expression is associated with synovitis severity in rheumatoid arthritis patients. Ann. Rheum. Dis. 71 (2012), 150–154.
13. Hwang, S., Choi, B., Kang, S., Chang, J., Kim, Y., Chung, Y., et al. Inteleukin-34 produced by human fibroblast-like synovial cells in rheumatoid arthritis supports osteoclastogenesis. Arthritis Res. Ther., 14, 2012, R14.
14. Yang, S., Jiang, S., Wang, Y., Tu, S., Wang, Z., Chen, Z., et al. Interleukin 34 upregulation contributes to the increment of MicroRNA 21 expression through STAT3 activation associated with disease activity in rheumatoid arthritis. J. Rheumatol. 43:7 (2016), 1312–1319.
15. Moon, S., Hong, Y., Ju, J., Kwok, S., Park, S., Min, J., Increased levels of interleukin 34 in serum and synovial fluid are associated with rheumatoid factor and anticyclic citrullinated peptide antibody titers in patients with rheumatoid arthritis. J. Rheumatol. 40:11 (2013), 1842–1849.
16. Chemel, M., Brion, R., Segaliny, A., Lamora, A., Charrier, C., Brulin, B., et al. Bone morphogenetic protein 2 and transforming growth factor β1 inhibit the expression of the proinflammatory cytokine IL-34 in rheumatoid arthritis synovial fibroblasts. Am. J. Pathol. 187:1 (2017), 156–162.
17. Tian, Y., Shen, H., Xia, L., Lu, J., Elevated serum and synovial fluid levels of interleukin-34 in rheumatoid arthritis: possible association with disease progression via interlukin-17 production. J. Interferon Cytokine Res. 33:7 (2013), 398–401.
18. Chang, S., Choi, B., Choi, J., Yoo, J., Ha, Y., Cho, H., et al. Baseline serum interleukin-34 levels independently predict radiographic progression in patients with rheumatoid arthritis. Rheumatol. Int. 35 (2015), 71–79.
19. Ding, R., Li, P., Song, D., Zhang, X., Bi, L., Predictors of response to TNF-α antagonist therapy in Chinese rheumatoid arthritis. Clin. Rheumatol. 34 (2015), 1203–1210.
20. Zhang, F., Ding, R., Li, P., Ma, C., Song, D., Wang, X., et al. Interluekin-34 in rheumatoid arthritis: potential role in clinical therapy. Int. J. Clin. Exp. Med. 8:5 (2015), 7809–7815.
21. B. Wang, Z. Ma, M. Wang, X. Sun, Y. Tang, M. Li, et al., IL-34 upregulated Th17 production through increased IL-6 expression by rheumatoid fibroblast-like synoviocytes, Mediators Inflamm., 2017. doi:10.1155.
22. Bethunaickan, R., Berthier, C., Zhang, W., Kretzler, M., Davidson, A., Comparative transcriptional profiling of 3 murine models of SLE nephritis reveals both unique and shared regulatory networks. PLOS One, 8, 2013, e77489.
23. H. Wang, J. Cao, X. Lai, Serum interleukin-34 levels are elevated in patients with systemic lupus erythematosus, Molecules 22 (2017) 35. doi:10.3390.
24. + monocytes. Rheumatology 52 (2013), 1009–1017.
25. Li, J., Liu, L., Rui, W., Li, X., Xuan, D., Zheng, S., et al. New Interleukins in Psoriasis and Psoriatic arthritis: the possible roles on interleukin-33 to interleukin-38 in disease activities and bone erosions. Dermatology 233:1 (2017), 37–46.
26. Weisberg, S.P., McCann, D., Desai, M., Rosenbaum, M., Leibel, R.L., Ferrante, A.W., Obesity is associated with macrophage accumulation in adipose tissues. J. Clin. Invest. 112:12 (2003), 1796–1808.
27. Chang, E., Lee, S., Song, Y., Jang, Y., Park, H., Hong, J., et al. IL-34 is associated with obesity, chronic inflammation, and insulin resistance. J. Clin. Endocrinal. Metab. 99 (2014), 1263–1271.
28. Below, J., Gamazon, E., Morrison, J., Konkashbaev, A., Pluzhnikov, A., McKeigue, P., et al. Genome-wide association and meta-analysis in populations from Starr County, Texas, and Mexico City identify type 2 diabetes susceptibility loci and enrichment for expression quantitative trait loci in top signals. Diabetologia 54 (2011), 2047–2055.
29. Liao, L., Chen, C., Wu, F., Lin, C., Hsiao, J., Chang, C., et al. Identified single-nucleotide polymorphisms and haplotypes at 16q22.1 increase diabetic nephropathy risk in Han Chinese population. BMC Genet., 15, 2014, 113.
30. Zorena, K., Jachimowicz-Duda, O., Waz, P., The cut-off value for interleukin 34 as an additional potential inflammatory biomarker for the prediction of the risk of diabetic complications. Biomarkers 21:3 (2016), 276–282.
31. Li, Z., Jin, D., Wu, Y., Zhang, K., Hu, P., Cao, X., et al. Increased serum interleukin-34 in patients with coronary artery disease. J. Int. Med. Res. 40 (2012), 1866–1870.
32. Fan, Q., Yan, X., Zhang, H., Lu, L., Qi, Zhang, Wang, F., et al. IL-34 is associated with the presence and severity of renal dysfunction and coronary artery disease in patients with heart failure. Sci. Rep., 6, 2016, 39324.
33. Tao, R., Fan, Q., Zhang, H., Xie, H., Lu, L., Gu, G., et al. Prognostic significance of interleukin-34 (IL-34) in patients with chronic heart failure with or without renal insufficiency. J. Am. Heart Assoc., 6(4), 2017, e004911.
34. Shoji, H., Yoshio, S., Mano, Y., Kumagai, E., Sugiyama, M., Korenaga, M., et al. Interleukin-34 as a fibroblast-derived marker of liver fibrosis in patients with non-alcoholic fatty liver disease. Sci. Rep., 6, 2016, 28814.
35. Lee, S., Huen, S., Nishio, H., Lee, H.K., Choi, B.S., Ruhrberg, C., et al. Distinct macrophage phenotypes contribute to kidney injury and repair. J. Am. Soc. Nephrol. 22:2 (2011), 317–326.
36. Lech, M., Gröbmayr, R., Ryu, M., Lorenz, G., Hartter, I., Mulay, S.R., et al. Macrophage phenotype controls long-term AKI outcomes-kidney regeneration versus atrophy. J. Am. Son. Nephrol. 25:2 (2014), 292–304.
37. Menke, J., Iwata, Y., Rabacal, W.A., Basu, R., Yeung, Y.G., Humphreys, B.D., et al. Menke CSF-1 signals directly to renal tubular epithelial cells to mediate repair in mice. J. Clin. Invest. 119:8 (2009), 2330–2342.
38. Baek, J., Zeng, R., Weinmann-Menke, J., Valerius, M., Wada, Y., Ajay, A., et al. IL-34 mediates acute kidney injury and worsens subsequent chronic kidney disease. J. Clin. Invest. 125:8 (2015), 3198–3214.
39. Zwicker, S., Martinez, G., Bosma, M., Gerling, M., Clark, R., Majster, M., et al. Interleukin 34: a new modulator of human and experimental inflammatory bowel disease. Clin. Sci. 129:3 (2015), 281–290.
40. Franzè, E., Monteleone, I., Cupi, M.L., Mancia, P., Caprioli, F., Marafini, I., et al. Interluekin-34 sustains inflammatory pathways in the gut. Clin. Sci. 129:3 (2015), 271–280.
41. Franzè, E., Marafini, I., De Simone, V., Monteleone, I., Caprioli, F., Colantoni, A., et al. Interleukin-34 induces Cc-chemokine ligand 20 in gut epithelial cells. J. Crohns Colitis 10:1 (2016), 87–94.
42. Esaki, H., Ewald, D., Ungar, B., Rozenblit, M., Zheng, X., Xu, H., et al. Identification of novel immune and barrier genes in atopic dermatitis by means of laser capture microdissection. J. Allergy Clin. Immunol. 135:1 (2015), 153–163.
43. Chitu, V., Gokhan, S., Nandi, S., Mehler, M., Stanley, E., Emerging roles for CSF-1 receptor and its ligands in the nervous system. Trends Neurosci. 39:6 (2016), 378–393.
44. Nandi, S., Gokhan, S., Dai, X., Wei, S., Enikolopov, G., Lin, H., et al. The CSF-1 receptor ligands IL-34 and CSF-1 exhibit distinct developmental brain expression patterns and regulate neural progenitor cell maintenance and maturation. Dev. Biol. 367:2 (2012), 100–113.
45. Bohlen, C.J., Bennett, F.C., Tucker, A.F., Collins, H.Y., Mulinyawe, S.B., Barres, B.A., Diverse requirements for microglial survival, specification, and function revealed by defined-medium cultures. Neuron 94:4 (2017), 759–773.
46. T. Mizuno, Y. Doi, H. Mizoguchi, S. Jin, M. Noda, Y. Sonobe, et al., Interleukin-34 selectively enhances the neuroprotective effects of microglia to attenuate oligomeric amyloid-β neurotoxicity, Am. J. Pathol. 179 (2011) 2016–2027.
47. D. Ma, Y. Doi, S. Jin, E. Li, Y. Sonobe, H. Takeuchi, et al., TGF-β induced by interleukin-34-stimulated microglia regulates microglial proliferation and attenuates oligomertric amyloid β neurotoxicity, Neurosci. Lett. 529(1) (2012) 86–91.
48. Jin, S., Sonobe, Y., Kawanokuchi, J., Horiuchi, H., Cheng, Y., Wang, Y., et al. Interleukin-34 restores blood-brain barrier integrity by upregulating tight junction proteins in endothelial cells. PLOS ONE, 9(12), 2014, e115981.
49. Luo, J., Elwood, F., Britschgi, M., Villeda, S., Zhang, H., Ding, Z., et al. Colony-stimulating factor 1 receptor (CSF1R) signaling in injured neurons facilitates protection and survival. J. Exp. Med. 210:1 (2013), 157–172.
50. Zhu, C., Herrmann, U., Falsig, J., Abakumova, I., Nuvolone, M., Schwarz, P., et al. A neuroprotective role for microglia in prion diseases. J. Exp. Med. 213:6 (2016), 1047–1059.
51. Preisser, L., Miot, C., Le Guillou-Guillemette, H., Beaumont, E., Foucher, E.D., Garo, E., et al. IL-34 and macrophage colony-stimulating factor are overexpressed in hepatitis C virus fibrosis and induce profibrotic macrophages that promote collagen synthesis by hepatic stellate cells. Hepatology 60:6 (2014), 1879–1890.
52. Yu, G., Bing, Y., Zhu, S., Li, W., Xia, L., Li, Y., et al. Activation of the interleukin-34 inflammatory pathway in response to influenza A virus infection. Am. J. Med. Sci. 349:2 (2015), 145–150.
53. Covaleda, L., Fuller, F., Payne, S., EIAV2 S2 enhances pro-inflammatory cytokine and chemokine response in infected macrophages. Virology 397 (2010), 217–223.
54. Gerngross, L., Lehmicke, G., Belkadi, A., Fischer, T., Role for cFMS in maintaining alternative macrophage polarization in SIV infection: implications for HIV neuropathogenesis. J. Neuroinflamm., 12, 2015, 58.
55. Cheng, S., Tang, H., Ren, J., Chen, X., Huang, A., Chen, J., Interleukin-34 inhibits hepatitis B virus replication in vitro and in vivo. PLOS ONE, 12(6), 2017, e0179605.
56. Wang, T., Kono, T., Monte, M., Kuse, H., Costa, M., Korenaga, H., et al. Identification of IL-34 in teleost fish: differential expression of rainbow trout IL-34, MCSF1 and MCSF2, ligands of the MCSF receptor. Mol. Immunol. 53 (2013), 398–409.
57. Mo, Z., Li, Y., Zhou, L., Li, A., Luo, X., Dan, X., Grouper (Epinephelus coioides) IL-34/MCSF2 and MCSFR1/MCSFR2 were involved in mononuclear phagocytes activation against Cryptocaryon irritans infection. Fish Shellfish Immunol. 43 (2015), 142–149.
58. San Segundo, D., Ruiz, P., Irure, J., Arias-Loste, M.T., Cuadrado, A., Puente, A., et al. Serum levels of interleukin-34 during acute rejection in liver transplantation. Transplant. Proc. 48:9 (2016), 2977–2979.
59. Bézie, S., Picarda, E., Ossart, J., Tesson, L., Usal, C., Renaudin, K., et al. IL-34 is a Treg-specific cytokine and mediates transplant tolerance. J. Clin. Invest. 125:10 (2015), 3952–3964.
60. Ségaliny, A., Mohamadi, A., Dizier, B., Lokajczyk, A., Brion, R., Lanel, R., et al. Interleukin-34 promotes tumor progression and metastatic process in osteosarcoma through induction of angiogenesis and macrophage recruitment. Int. J. Cancer 137 (2015), 73–85.
61. Baghdadi, M., Wada, H., Nakanishi, S., Abe, H., Han, H., Putra, W., et al. Chemotherapy-induced IL34 enhances immunosuppression by tumor-associated macrophages and mediates survival of chemoresistant lung cancer cells. Cancer Res. 76:20 (2016), 6030–6042.
62. Rietkötter, E., Bleckmann, A., Bayerlová, M., Menck, K., Chuang, H., Wenske, B., et al. Anti-CSF-1 treatment is effective to prevent carcinoma invasion induced by monocyte-derived cells but scarcely by microglia. Oncotarget 6:17 (2015), 15482–15493.
63. M. Baud'huin, R. Renault, C. Charrier, A. Riet, A. Moreau, R. Brion, et al., Interluekin-34 is expressed by giant cell tumors of bone and plays a key role in RANKL-induced osteoclastogenesis, J. Pathol. 221 (2010) 77–86.
64. Cioce, M., Canino, C., Goparaju, C., Yang, H., Carbone, M., Pass, H.I., Autocrine CSF-1R signaling drives mesothelioma chemoresistance via AKT activation. Cell Death Dis., 5, 2014, e1167.
65. Zhou, S., Hu, Z., Zhou, Z., Dai, Z., Wang, Z., Cao, Y., et al. miR-28-5p-IL-34-macrophage feedback loop modulates hepatocellular carcinoma metastasis. Hepatology 63:5 (2016), 1560–1575.
66. Raggi, C., Correnti, M., Sica, A., Andersen, J., Cardinale, V., Alvaro, D., Chiorino, G., et al. Cholangiocarcinoma stem-like subset shapes tumor-initiating niche by educating associated macrophages. J. Hepatol. 66:1 (2017), 102–115.
67. Wang, B., Xu, W., Tan, M., Xiao, Y., Yang, H., Xia, T., Integrative genomic analysis of a novel cytokine, interleukin-34 and its potential role in cancer prediction. Int. J. Mol. Med. 35:1 (2015), 92–102.
68. Nandi, S., Cioce, M., Yeung, Y., Nieves, E., Tesfa, L., Lin, H., et al. Receptor-type protein-tyrosine phosphatase ζ is a functional receptor for interleukin-34. J. Biol. Chem. 288:30 (2013), 21972–21986.
69. Booker, B., Clark, R., Pellom, S., Adunyah, S., Interleukin-34 induces monocyte-like differentiation in leukemia cell lines. Int. J. Biochem. Mol. Biol. 6:1 (2015), 1–16.
70. Segaliny, A., Brion, R., Mortier, E., Maillasson, M., Cherel, M., Jacques, Y., et al. Syndecan-1 regulates the biological activities of interleukin-34. Biochim. Biophys. Acta 1853:5 (2015), 1010–1021.
71. Dai, X.M., Ryan, G.R., Hapel, A.J., Dominguez, M.G., Russell, R.G., Kapp, S., et al. Targeted disruption of the mouse colony-stimulating factor 1 receptor gene results in osteopetrosis, mononuclear phagocyte deficiency, increased primitive progenitor cell frequencies, and reproductive defects. Blood 99 (2002), 111–120.
72. E. Stanley, Chitu Violeta, CSF-1 receptor signaling in myeloid cells, Cold Spring Harb. Perspect. Biol. 6 (2014) a021857.
73. Guillonneau, C., Bezie, S., Anegon, I., Immunoregulatory properties of the cytokine IL-34. Cell Mol. Life Sci. 74:14 (2017), 2569–2586.
74. Zwicker, S., Bureik, D., Bosma, M., Martinez, G.L., Almer, S., Boström, E.A., receptor-type protein-tyrosine phosphatase ζ and colony stimulating factor-1 receptor in the intestine: cellular expression and cytokine- and chemokine responses by interleukin-34 and colony stimulating factor-1. PLOS ONE, 11(11), 2016, e0167324.
75. Masteller, E., Wong, B., Targeting IL-34 in chronic inflammation. Drug Discov. Today 19:8 (2014), 1212–1216.